Johnson & Johnson (NYSE:JNJ) Shares Sold by AdvisorNet Financial Inc

AdvisorNet Financial Inc reduced its stake in Johnson & Johnson (NYSE:JNJ) by 11.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,117 shares of the company’s stock after selling 1,421 shares during the period. AdvisorNet Financial Inc’s holdings in Johnson & Johnson were worth $1,608,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. First Financial Corp IN grew its position in shares of Johnson & Johnson by 15.0% in the 4th quarter. First Financial Corp IN now owns 3,135 shares of the company’s stock valued at $453,000 after buying an additional 408 shares during the last quarter. Signet Financial Management LLC grew its holdings in shares of Johnson & Johnson by 11.0% during the fourth quarter. Signet Financial Management LLC now owns 17,940 shares of the company’s stock worth $2,594,000 after purchasing an additional 1,775 shares during the last quarter. PFW Advisors LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth about $2,093,000. Catalyst Private Wealth LLC boosted its position in shares of Johnson & Johnson by 6.3% in the 4th quarter. Catalyst Private Wealth LLC now owns 2,045 shares of the company’s stock valued at $296,000 after purchasing an additional 121 shares during the period. Finally, Marion Wealth Management grew its stake in Johnson & Johnson by 11.4% during the 4th quarter. Marion Wealth Management now owns 1,626 shares of the company’s stock worth $235,000 after buying an additional 167 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on JNJ. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Wells Fargo & Company raised their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, Guggenheim upped their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.71.

Johnson & Johnson Trading Up 0.1 %

Shares of JNJ stock opened at $144.68 on Wednesday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business’s fifty day moving average price is $149.12 and its 200 day moving average price is $156.09. The firm has a market capitalization of $348.33 billion, a PE ratio of 20.94, a P/E/G ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the firm posted $2.66 EPS. The business’s revenue was up 5.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.43%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.